{"id":"meningococcal-a-control","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The meningococcal A vaccine contains purified polysaccharide antigen from the serogroup A capsule of Neisseria meningitidis. Upon administration, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies (primarily IgG) that bind to the bacterial capsule and facilitate complement-mediated bactericidal killing and opsonophagocytosis. This provides immunity against invasive meningococcal disease caused by serogroup A strains.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup A polysaccharide capsule.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:54:23.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup A"}]},"trialDetails":[{"nctId":"NCT04350138","phase":"PHASE2","title":"Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-29","conditions":"Gonococcal Infection","enrollment":2606},{"nctId":"NCT05766904","phase":"PHASE3","title":"Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-04","conditions":"Gonorrhea, Sexually Transmitted Infection","enrollment":150},{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT04704830","phase":"PHASE3","title":"R21/Matrix-M in African Children Against Clinical Malaria","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2021-04-29","conditions":"Malaria","enrollment":4800},{"nctId":"NCT07395739","phase":"PHASE1","title":"A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)","startDate":"2026-02-24","conditions":"Neisseria Meningitidis Serogroup B","enrollment":30},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT07204457","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old","status":"RECRUITING","sponsor":"EyeGene Inc.","startDate":"2025-10-15","conditions":"Meningococcal Infections","enrollment":1123},{"nctId":"NCT07252804","phase":"PHASE4","title":"Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-01","conditions":"Autoimmune Rheumatologic Disease","enrollment":263},{"nctId":"NCT05480800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-09-13","conditions":"Salmonella Infections","enrollment":155},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT06700148","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-12-14","conditions":"Meningococcal Meningitis","enrollment":840},{"nctId":"NCT06226714","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-01","conditions":"Meningococcal Meningitis","enrollment":840},{"nctId":"NCT06446752","phase":"PHASE3","title":"BIYELA - Bexsero Immunisation in Young Women in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-08-14","conditions":"Gonorrhea, Gonorrhea of Pharynx, Gonorrhea of Anus","enrollment":1100},{"nctId":"NCT06011200","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-09-16","conditions":"Epidemic Meningitis","enrollment":1000},{"nctId":"NCT04886154","phase":"PHASE1, PHASE2","title":"A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-14","conditions":"Infections, Meningococcal","enrollment":1440},{"nctId":"NCT03299426","phase":"PHASE3","title":"Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2018-02-21","conditions":"Typhoid","enrollment":30000},{"nctId":"NCT03295318","phase":"PHASE2","title":"Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2017-11-15","conditions":"Meningitis, Meningococcal","enrollment":375},{"nctId":"NCT06131554","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1480},{"nctId":"NCT04415424","phase":"PHASE3","title":"Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2021-07-08","conditions":"Neisseria Gonorrheae Infection","enrollment":650},{"nctId":"NCT03562377","phase":"PHASE2","title":"Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-07-13","conditions":"Atopic Dermatitis","enrollment":215},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT04707391","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-25","conditions":"Meningitis, Meningococcal","enrollment":1250},{"nctId":"NCT05252715","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-18","conditions":"Meningitis, Meningococcal","enrollment":1200},{"nctId":"NCT06314880","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-07-22","conditions":"Healthy Volunteers","enrollment":300},{"nctId":"NCT06314659","phase":"PHASE3","title":"Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-09-17","conditions":"Healthy Population","enrollment":630},{"nctId":"NCT06314685","phase":"PHASE3","title":"Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-10","conditions":"Healthy Population","enrollment":2450},{"nctId":"NCT06337071","phase":"PHASE2","title":"A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Aimei Vacin BioPharm (Zhejiang) Co., Ltd.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1200},{"nctId":"NCT04852185","phase":"PHASE4","title":"Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2021-08-24","conditions":"Typhoid Fever","enrollment":23000},{"nctId":"NCT04502693","phase":"PHASE3","title":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-14","conditions":"Infections, Meningococcal","enrollment":3657},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT06165276","phase":"PHASE1","title":"A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07-25","conditions":"Meningococcal Immunization","enrollment":285},{"nctId":"NCT03135834","phase":"PHASE3","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-04-24","conditions":"Meningococcal Vaccine","enrollment":1610},{"nctId":"NCT04450498","phase":"PHASE4","title":"A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years","status":"COMPLETED","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2020-12-23","conditions":"Neisseria Meningitides Meningitis","enrollment":260},{"nctId":"NCT04440163","phase":"PHASE3","title":"MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":2431},{"nctId":"NCT05298644","phase":"PHASE2, PHASE3","title":"COVID-19 Paediatric VLA2001-321 Study","status":"WITHDRAWN","sponsor":"Valneva Austria GmbH","startDate":"2022-10-01","conditions":"SARS-CoV-2 Infection","enrollment":""},{"nctId":"NCT02509494","phase":"PHASE3","title":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-30","conditions":"Ebola Virus Disease","enrollment":1023},{"nctId":"NCT02324751","phase":"PHASE2","title":"Vaccines Against Salmonella Typhi","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-09","conditions":"Typhoid Fever, Enteric Fever","enrollment":112},{"nctId":"NCT00875524","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-03","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":180},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT01187433","phase":"PHASE2","title":"Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08","conditions":"Dengue, Dengue Hemorrhagic Fever","enrollment":150},{"nctId":"NCT03694405","phase":"PHASE4","title":"Adolescent MenACWY Booster Study","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-09-20","conditions":"Meningococcal Disease, Invasive","enrollment":244},{"nctId":"NCT05229536","phase":"PHASE2","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2018-12-21","conditions":"Meningitis, Meningococcal","enrollment":720},{"nctId":"NCT01939158","phase":"PHASE3","title":"Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-02","conditions":"Infections, Meningococcal","enrollment":803},{"nctId":"NCT04358731","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-12-27","conditions":"Vaccine for Meningococcal Disease","enrollment":1640},{"nctId":"NCT04204096","phase":"PHASE3","title":"Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2020-02-04","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT03274102","phase":"PHASE4","title":"Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2017-04-22","conditions":"Hand, Foot and Mouth Disease","enrollment":780},{"nctId":"NCT03964012","phase":"PHASE3","title":"Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-08-20","conditions":"Meningococcal Meningitis","enrollment":1800},{"nctId":"NCT02810340","phase":"PHASE1","title":"Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2016-08-01","conditions":"Meningococcal Vaccines","enrollment":60},{"nctId":"NCT03746665","phase":"PHASE3","title":"Maternal Immunization With MenAfriVac™","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2018-12-19","conditions":"Meningitis, Meningococcal","enrollment":200},{"nctId":"NCT04689165","phase":"PHASE3","title":"A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine","status":"UNKNOWN","sponsor":"Wei Cun","startDate":"2020-09-14","conditions":"Meningitis, Meningococcal","enrollment":1280},{"nctId":"NCT04689191","phase":"PHASE3","title":"A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine","status":"UNKNOWN","sponsor":"Wei Cun","startDate":"2020-09-15","conditions":"Meningitis, Meningococcal","enrollment":1280},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT02173704","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-11","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":225},{"nctId":"NCT02451514","phase":"PHASE2","title":"A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-30","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":129},{"nctId":"NCT01272180","phase":"PHASE2","title":"Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-08","conditions":"Invasive Meningococcal Disease","enrollment":484},{"nctId":"NCT02986854","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-08","conditions":"Infections, Meningococcal","enrollment":704},{"nctId":"NCT01430689","phase":"PHASE4","title":"Maternal Flu Vaccine Trial in Bamako, Mali","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-09-12","conditions":"Influenza","enrollment":4193},{"nctId":"NCT01340898","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-27","conditions":"Meningococcal Infection","enrollment":753},{"nctId":"NCT02212457","phase":"PHASE2","title":"Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-21","conditions":"Infections, Meningococcal","enrollment":1063},{"nctId":"NCT02456077","phase":"NA","title":"Strengthening Physician Communication About HPV Vaccines","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-02-01","conditions":"HPV Immunization Status","enrollment":93582},{"nctId":"NCT01900899","phase":"PHASE3","title":"Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07","conditions":"Infections, Meningococcal","enrollment":184},{"nctId":"NCT01682876","phase":"PHASE3","title":"Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-07","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":715},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT00661713","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-06","conditions":"Meningococcal Disease","enrollment":1631},{"nctId":"NCT02676895","phase":"PHASE2","title":"A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-08","conditions":"Shigella Sonnei Infection","enrollment":74},{"nctId":"NCT01461993","phase":"PHASE2","title":"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-28","conditions":"Vaccines, Meningococcal Vaccines","enrollment":2499},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT02446743","phase":"PHASE3","title":"Combined Study - Phase 3b MenB Long Term Persistence in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-17","conditions":"Infections, Meningococcal","enrollment":531},{"nctId":"NCT03714737","phase":"PHASE3","title":"Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2016-05-12","conditions":"Vaccine","enrollment":1950},{"nctId":"NCT02080559","phase":"PHASE4","title":"Investigating the Immune Response to 4CMenB in Infants","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-07-21","conditions":"Meningitis","enrollment":187},{"nctId":"NCT00329849","phase":"PHASE3","title":"Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-05","conditions":"Meningococcal Disease","enrollment":1500},{"nctId":"NCT02285777","phase":"PHASE2","title":"Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-01","conditions":"Meningococcal Disease","enrollment":189},{"nctId":"NCT02140762","phase":"PHASE2","title":"Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-05","conditions":"Meningococcal Disease","enrollment":305},{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT00129116","phase":"PHASE2","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":388},{"nctId":"NCT00129129","phase":"PHASE2","title":"Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-08-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":756},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT01867463","phase":"PHASE1","title":"Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-27","conditions":"Malaria","enrollment":230},{"nctId":"NCT00262041","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-10","conditions":"Prevention of Meningococcal Disease","enrollment":524},{"nctId":"NCT01345721","phase":"PHASE3","title":"Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Meningococcal Disease","enrollment":205},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":"Infections, Meningococcal","enrollment":461},{"nctId":"NCT03263403","phase":"PHASE2, PHASE3","title":"Non Inferiority Trial of Locally Manufactured Meningococcal ACWY Vaccine 'Ingovax ACWY' in Bangladesh.","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2017-08-21","conditions":"Meningococcal Vaccine","enrollment":88},{"nctId":"NCT00657709","phase":"PHASE3","title":"Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Serogroup B Meningococcal Meningitis","enrollment":3630},{"nctId":"NCT01148017","phase":"PHASE3","title":"Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-07","conditions":"Meningococcal Meningitis","enrollment":433},{"nctId":"NCT02141516","phase":"PHASE3","title":"Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.","status":"COMPLETED","sponsor":"Novartis","startDate":"2014-05","conditions":"Meningococcal Disease","enrollment":239},{"nctId":"NCT00345579","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4432},{"nctId":"NCT00297817","phase":"PHASE2","title":"Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-02","conditions":"Meningococcal Disease","enrollment":203},{"nctId":"NCT00345683","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4021},{"nctId":"NCT01992536","phase":"PHASE2","title":"Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-12","conditions":"Meningococcal Disease","enrollment":194},{"nctId":"NCT00126984","phase":"PHASE2","title":"Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-07","conditions":"Infections, Meningococcal","enrollment":508},{"nctId":"NCT02377843","phase":"NA","title":"Making Effective Human Papillomavirus (HPV) Vaccine Recommendations","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-03","conditions":"Human Papillomavirus","enrollment":30},{"nctId":"NCT01830855","phase":"PHASE3","title":"A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Meningococcal Vaccine","enrollment":3596},{"nctId":"NCT00518180","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis","enrollment":1620},{"nctId":"NCT01214850","phase":"PHASE3","title":"Novartis Vaccine and Diagnostics Carriage Trial","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"N. Meningitidis Carriage","enrollment":2968}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":81,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Meningococcal A (control)","genericName":"Meningococcal A (control)","companyName":"International Vaccine Institute","companyId":"international-vaccine-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup A polysaccharide capsule. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup A.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}